OXU-005 is a potential first-in-class, long-lasting treatment for diabetic retinopathy. OXU-005 contains a proprietary narrow spectrum kinase inhibitor with potent anti-angiogenic and anti-inflammatory properties. OXU-005 will be prepared using long-lasting Oxuspheres and is designed to be delivered via Oxulumis to the posterior suprachoroidal space. Preclinical studies with OXU-005 demonstrate encouraging efficacy compared to benchmark clinical …
OXU-001 is being developed to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory for the treatment of DME, RVO and uveitis. Given this product profile, there is potential to expand OXU-001 development to radiation maculopathy and specifically to radiation-induced macular edema. OXU-001 are dexamethasone-containing Oxuspheres that are designed to be …
OXU-001 is being developed to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory for the treatment of DME, RVO and uveitis. Given this product profile and its delivery to the middle layers of the eye via Oxulumis, there is potential to expand OXU-001 development to radiation maculopathy and specifically to …
OXU-003 is a potential first-in-class registered treatment for retinoblastoma. OXU-003 is an innovative stable, sustained-release preparation of a proprietary chemotherapy agent. It is designed to be safely delivered in the suprachoroidal space, adjacent to primary retinoblastoma tumors using Oxulumis microcatheter. Once delivered, OXU-003 is designed to release the anti-cancer drug over prescribed treatment cycles. The …
OXU-001 is being developed to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory for the treatment of DME, RVO and uveitis. Given this product profile, there is potential to expand OXU-001 development to radiation maculopathy and specifically to radiation-induced macular edema. OXU-001 are dexamethasone-containing Oxuspheres that are designed to be …
OXU-001 is being developed to provide retinal specialists with a potent, long-lasting, safe, and broad-acting anti-edema and anti-inflammatory for the treatment of DME, RVO and uveitis. Given this product profile and its delivery to the middle layers of the eye via Oxulumis, there is potential to expand OXU-001 development to radiation maculopathy and specifically to …
OXU-005 is a potential first-in-class, long-lasting treatment for diabetic retinopathy. OXU-005 contains a proprietary narrow spectrum kinase inhibitor with potent anti-angiogenic and anti-inflammatory properties. OXU-005 will be prepared using long-lasting Oxuspheres and is designed to be delivered via Oxulumis to the posterior suprachoroidal space. Preclinical studies with OXU-005 demonstrate encouraging efficacy compared to benchmark clinical …
General
+44 (0)1865 636200
inquiries@oxular.com
Magdalen Centre
1 Robert Robinson Avenue
Oxford, OX4 4GA, UK
Limited company registered in
England and Wales
Registration No. 09331313
VAT No. GB 244 5883 81
Copyright Oxular Limited
Media
+1 617 895 9511
monique@thrustsc.com
Monique Allaire
Thrust
Follow us on
Limited company registered in England and Wales (Registration No. 09331313) VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting
